Table 1 Correlations between EIF5A2 expression and clinicopathologic characteristics of EOC patients
From: EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis
| Characteristics | All cases | EIF5A2 protein | P value | |
|---|---|---|---|---|
| Low expression | High expression | |||
| Age (years, mean) | 76 | 57 | 55 | 0.28 |
| Histological type | 0.201 | |||
| Serous | 61 | 25 (41.0%) | 36 (59.0%) | |
| Others | 15 | 9 (60.0%) | 6 (40.0%) | |
| Histological grade | 0.724 | |||
| Well/moderate | 10 | 5 (50.0%) | 5 (50.0%) | |
| Poorly | 66 | 29 (43.9%) | 37 (56.1%) | |
| Lymphatic metastasis | 0.108 | |||
| No | 63 | 30 (47.6%) | 33 (52.4%) | |
| Yes | 13 | 4 (30.8%) | 9 (69.2%) | |
| FIGO stage | 0.263 | |||
| IIIc | 58 | 28 (48.3%) | 30 (51.7%) | |
| IV | 18 | 6 (33.3%) | 12 (66.7%) | |
| Residual disease | 0.381 | |||
| ≤ 10 mm | 59 | 28 (47.5%) | 31 (52.5%) | |
| > 10 mm | 17 | 6 (35.3%) | 11 (64.7%) | |
| Clinical response | 0.039 | |||
| Complete | 68 | 33 (48.5%) | 35 (51.5%) | |
| Partial | 7 | 1 (14.3%) | 6 (85.7%) | |
| Non-response | 1 | 0 (0.0%) | 1 (100.0%) | |
| Platinum sensitivity | 0.014 | |||
| Sensitive | 60 | 31 (51.7%) | 29 (48.3%) | |
| Resistant* | 16 | 3 (18.8%) | 13 (81.2%) | |